Acer Therapeutics Financials
ACERDelisted Stock | USD 0.84 0.02 2.33% |
Acer |
Understanding current and past Acer Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Acer Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Acer Therapeutics' assets may result in an increase in income on the income statement.
Acer Therapeutics Stock Summary
Acer Therapeutics competes with Pasithea Therapeutics, SAB Biotherapeutics, Lexaria Bioscience, ZyVersa Therapeutics, and Biodexa Pharmaceticals. Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts. Acer Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people.Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US00444P1084 |
Business Address | One Gateway Center, |
Sector | Pharmaceuticals |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.acertx.com |
Phone | 844 902 6100 |
Currency | USD - US Dollar |
Acer Therapeutics Key Financial Ratios
Acer Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Acer Therapeutics's current stock value. Our valuation model uses many indicators to compare Acer Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Acer Therapeutics competition to find correlations between indicators driving Acer Therapeutics's intrinsic value. More Info.Acer Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Acer Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Acer Therapeutics Market Pulse
Quote | 0.84 |
Change(%) | 2.33 |
Change | 0.02 |
Open | 0.86 |
Low | 0.83 |
High | 0.86 |
Volume | 0 |
Exchange | NASDAQ |
Steps to analyze company Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Acer Therapeutics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Acer has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Acer Therapeutics' financials are consistent with your investment objective using the following steps:- Review Acer Therapeutics' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Acer Therapeutics' liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Acer Therapeutics' financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Acer Therapeutics' stock is overvalued or undervalued.
Acer Therapeutics December 16, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Acer Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Acer Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Acer Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Acer Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Acer Therapeutics's daily price indicators and compare them against related drivers.
Information Ratio | (0.07) | |||
Maximum Drawdown | 21.89 | |||
Value At Risk | (7.37) | |||
Potential Upside | 8.33 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Consideration for investing in Acer Stock
If you are still planning to invest in Acer Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acer Therapeutics' history and understand the potential risks before investing.
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Stocks Directory Find actively traded stocks across global markets | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Money Managers Screen money managers from public funds and ETFs managed around the world |